Koji Kabuto
BioVaxys, a biotechnology company focused on developing innovative vaccines, has recently executed an amendment to its Asset Purchase Agreement (APA) with Horizon Technology Finance Corp. This agreement will allow BioVaxys to further advance its research and development efforts in the field of immunotherapy.
The APA amendment signifies a significant milestone for BioVaxys, as it will provide the company with additional resources to accelerate the development of its novel vaccine technologies. With Horizon Technology Finance Corp’s support, BioVaxys aims to continue its mission of creating groundbreaking immunotherapies that have the potential to address unmet medical needs and improve patient outcomes.
One of BioVaxys’ most promising projects is its lead product candidate, Ovarian Cancer Immunotherapy (OVI). OVI is a novel vaccine designed to stimulate a patient’s immune system to target and destroy cancer cells, with the ultimate goal of improving survival rates for patients with ovarian cancer. The APA amendment will enable BioVaxys to advance the clinical development of OVI and potentially bring this innovative therapy to market in the near future.
In a statement regarding the APA amendment, BioVaxys’ CEO, James Passin, expressed his enthusiasm for the collaboration with Horizon Technology Finance Corp. He emphasized the importance of this partnership in driving BioVaxys’ mission forward and bringing transformative immunotherapies to patients in need.
Overall, the execution of the APA amendment between BioVaxys and Horizon Technology Finance Corp represents a significant step forward for the biotechnology company, signaling its commitment to advancing cutting-edge vaccine technologies and improving healthcare outcomes.
Source: PR Newswire
